Insight Molecular Diagnostics Inc.
IMDX
$4.01
$0.184.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 115.58% | 520.87% | 316.13% | 178.08% | 25.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 115.58% | 520.87% | 316.13% | 178.08% | 25.15% |
| Cost of Revenue | 65.05% | 231.20% | 166.01% | 106.86% | 5.09% |
| Gross Profit | 179.83% | 2,001.72% | 655.10% | 290.49% | 65.27% |
| SG&A Expenses | 19.99% | 26.15% | 27.88% | 15.46% | 4.52% |
| Depreciation & Amortization | -92.05% | -67.05% | -42.05% | -17.05% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.96% | 28.74% | 27.69% | 16.93% | 5.71% |
| Operating Income | -74.34% | -13.49% | -14.05% | -6.72% | -4.40% |
| Income Before Tax | 17.21% | -40.87% | -75.48% | -45.72% | -144.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.21% | -40.87% | -75.48% | -45.72% | -144.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.21% | -40.87% | -75.48% | -45.72% | -118.36% |
| EBIT | -74.34% | -13.49% | -14.05% | -6.72% | -4.40% |
| EBITDA | -74.18% | -10.28% | -12.35% | -6.36% | -5.32% |
| EPS Basic | 63.21% | 36.09% | 18.32% | 28.98% | -25.42% |
| Normalized Basic EPS | 32.85% | 54.74% | 47.60% | 45.23% | 36.37% |
| EPS Diluted | 46.89% | 36.09% | 18.32% | 28.98% | -25.41% |
| Normalized Diluted EPS | 32.85% | 54.74% | 47.60% | 45.23% | 36.35% |
| Average Basic Shares Outstanding | 133.26% | 148.49% | 135.85% | 111.89% | 70.85% |
| Average Diluted Shares Outstanding | 133.26% | 148.49% | 135.85% | 111.89% | 70.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |